Clinical Trials Logo

Tinea clinical trials

View clinical trials related to Tinea.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05881980 Not yet recruiting - Tinea Cruris Clinical Trials

Efficacy and Safety of Terbinafine and Itraconazole

Start date: May 2023
Phase: Phase 2/Phase 3
Study type: Interventional

There is a rise in the prevalence in recent years especially in tropical countries along with an increase in the number of treatment failures with chronic and recurrent dermatophytosis. There is a huge gap between the treatment required in the present scenario and the treatment guidelines given in the standard books. The aim of the study is to determine the effectiveness of terbinafine and itraconazole in different doses and in combination in the treatment of dermatophytosis. The study design will be a randomized parallel-group trial. Patients will be randomly divided into five parallel arms in which two of the standard drugs in recommended doses will be compared with their double doses and with a combination of both drugs. The patients will be reevaluated at 2, 4, 6, and 8 weeks of treatment (the end of therapy), using the physician Global Assessment (PGA) Scale. The cure will be considered a complete clinical resolution of the lesions. The patient's response to the treatment will be recorded. Safety and patient compliance will be recorded at each follow-up visit. Findings of observation will be recorded on a pre-prescribed and pre-tested data collection form. After collection, all data will be checked and compiled. Data will be processed and analyzed using computer software with statistical packages for social science SPSS-26. An analysis plan will be developed keeping in view the objectives of the study. The results of the continuous measurement will be presented on mean ± SD (mean-max) and results on categorical measurements will be presented in numbers (%). A p<0.05 will be considered statistically significant. Results will be disseminated to all Dermatology departments in Bangladesh.

NCT ID: NCT05730244 Not yet recruiting - Tinea Versicolor Clinical Trials

A Study of the Clinical Efficacy and Safety of 100% Cassia Alata Extract Against Tinea Versicolor

Start date: February 15, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to compare the effects of Cassia alata extract in treating tinea versicolor (ring worm skin condition) to placebo consisting of alcohol, green food colouring and glycerin in adult Jamaicans ages 18 to 89 years. The main questions the study aims to answer are:• Does the use of this extract heal the kills the ring worm fungus and clears up the rash faster compared to placebo • Does the use of this extract have significant side effects ie Is it safe compared to placebo. Participants will be asked to apply a small portion about 1 ml of the extract or placebo to the skin rash twice daily at least 8 hours and attend dermatology clinic every 4 weeks for 12 weeks.

NCT ID: NCT03471455 Not yet recruiting - Tinea Clinical Trials

Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis

ISORD
Start date: April 2018
Phase: Phase 2
Study type: Interventional

This study is a prospective, double blinded, randomized, pilot study to assess the effectiveness of oral low dose isotretinoin in combination with oral terbinafine and itraconazole in preventing recurrences in chronic recurrent dermatophytosis. The recruited patients will be randomized into four treatment arms; oral terbinafine alone and oral itraconazole alone versus oral isotretinoin in combination with each of these two antifungal agents. Randomization will be done using computer generated random number table. The patients in first treatment arm will receive 250 mg of oral terbinafine for 4 weeks, the patients in second treatment arm will receive oral itraconazole 200 mg twice a day for the same duration, while the patients in the third arm will receive oral terbinafine 250 mg once a day for 4 weeks with oral isotretinoin 20 mg once daily and patients in the fourth arm will receive oral itraconazole 200 mg twice a day for 4 weeks with oral isotretinoin 20 mg once daily. In the third and fourth arms, oral terbinafine and oral itraconazole respectively will be stopped after 4 weeks while oral isotretinoin will be continued for 6 months with monthly monitoring of liver function tests and fasting lipid profile.The patients will be followed at monthly intervals for recurrence and treated appropriately. The primary objective is to evaluate the effectiveness of low dose isotretinoin (20 mg/day) in preventing recurrences in chronic recurrent dermatophytosis by comparing the frequencies of recurrence in patients who are on low dose isotretinoin during the follow up versus those who are not comparing the disease free interval between the four randomized groups at monthly follow up for a total duration of 6 months.

NCT ID: NCT02491112 Not yet recruiting - Tinea Clinical Trials

A Randomized Study Evaluating the Safety and Efficacy of Luliconazole Cream in Pediatric Subjects With Tinea Corporis

Start date: October 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of Luliconazole Cream 1% when applied topically for 7 days in pediatric subjects 2 years to 17 years of age with tinea corporis.

NCT ID: NCT01105013 Not yet recruiting - Tinea Pedis Clinical Trials

Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections

Tonaftato
Start date: April 2012
Phase: Phase 3
Study type: Interventional

This is a study clinical, multicenter, Phase III trial, to evaluate the efficacy and safety of tolnaftate cream in the treatment of patients with fungal infections such as Tinea foot, Tinea and Tinea crural body.

NCT ID: NCT00848666 Not yet recruiting - Tinea Pedis Clinical Trials

Safety and Efficacy of a Novel Topical Therapy for Tinea Pedis (Athlete's Foot)

Start date: April 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of a novel topical therapy in patients with laboratory confirmed tinea pedis. During the follow-up period clinical and mycological examinations will be performed.